Detection of MMP-2 and MMP-9 activity in vivo with a triple-helical peptide optical probe.

We report a novel activatable NIR fluorescent probe for in vivo detection of cancer-related matrix metalloproteinase (MMP) activity. The probe is based on a triple-helical peptide substrate (THP) with high specificity for MMP-2 and MMP-9 relative to other members of the MMP family. MMP-2 and MMP-9 (also known as gelatinases) are specifically associated with cancer cell invasion and cancer-related angiogenesis. At the center of each 5 kDa peptide strand is a gelatinase sensitive sequence flanked by 2 Lys residues conjugated with NIR fluorescent dyes. Upon self-assembly of the triple-helical structure, the 3 peptide chains intertwine, bringing the fluorophores into close proximity and reducing fluorescence via quenching. Upon enzymatic cleavage of the triple-helical peptide, 6 labeled peptide chains are released, resulting in an amplified fluorescent signal. The fluorescence yield of the probe increases 3.8-fold upon activation. Kinetic analysis showed a rate of LS276-THP hydrolysis by MMP-2 (k(cat)/K(M) = 30,000 s(-1) M(-1)) similar to that of MMP-2 catalysis of an analogous fluorogenic THP. Administration of LS276-THP to mice bearing a human fibrosarcoma xenografted tumor resulted in a tumor fluorescence signal more than 5-fold greater than that of muscle. This signal enhancement was reduced by treatment with the MMP inhibitor Ilomostat, indicating that the observed tumor fluorescence was indeed enzyme mediated. These results are the first to demonstrate that triple-helical peptides are suitable for highly specific in vivo detection of tumor-related MMP-2 and MMP-9 activity.

[1]  W. Heindel,et al.  Synthesis and evaluation of a novel fluorescent photoprobe for imaging matrix metalloproteinases. , 2008, Bioconjugate chemistry.

[2]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.

[3]  G. Fields,et al.  Solid‐Phase synthesis and stability of triple‐helical peptides incorporating native collagen sequences , 1993, Biopolymers.

[4]  G. Fields,et al.  Use of Edman degradation sequence analysis and matrix-assisted laser desorption/ionization mass spectrometry in designing substrates for matrix metalloproteinases. , 2000, Journal of chromatography. A.

[5]  Y. Okada,et al.  Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas , 1996, International journal of cancer.

[6]  R. Weissleder,et al.  In vivo imaging of tumors with protease-activated near-infrared fluorescent probes , 1999, Nature Biotechnology.

[7]  Samuel Achilefu,et al.  Heptamethine cyanine dyes with a robust C-C bond at the central position of the chromophore. , 2006, The Journal of organic chemistry.

[8]  R. Klebe,et al.  Overview of matrix metalloproteinase expression in cultured human cells. , 1998, Matrix biology : journal of the International Society for Matrix Biology.

[9]  M. Radomski,et al.  N-substituted homopiperazine barbiturates as gelatinase inhibitors. , 2011, Bioorganic & medicinal chemistry.

[10]  E. Baker,et al.  Measuring gelatinase activity in colorectal cancer. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  J. Foidart,et al.  Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. , 1998, British Journal of Cancer.

[12]  Christoph Abels,et al.  Absorption and Fluorescence Spectroscopic Investigation of Indocyanine Green , 1996 .

[13]  R Weissleder,et al.  In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. , 2000, Cancer research.

[14]  Matthew Tirrell,et al.  Self-assembling amphiphiles for construction of protein molecular architecture , 1996 .

[15]  D. Leaper,et al.  Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging , 2000, The British journal of surgery.

[16]  Daniel J. Hawrysz,et al.  Developments toward diagnostic breast cancer imaging using near-infrared optical measurements and fluorescent contrast agents. , 2000, Neoplasia.

[17]  E. Novellino,et al.  Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. , 2011, European journal of medicinal chemistry.

[18]  Ralph Weissleder,et al.  Near-infrared optical imaging of proteases in cancer. , 2003, Molecular cancer therapeutics.

[19]  D. Grignon,et al.  Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  C. Bucana,et al.  Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  Z. Werb,et al.  Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. , 2010, Cancer research.

[22]  B. Packard,et al.  Profluorescent protease substrates: intramolecular dimers described by the exciton model. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Ralph Weissleder,et al.  In vivo molecular target assessment of matrix metalloproteinase inhibition , 2001, Nature Medicine.

[24]  R. Leblanc,et al.  Analysis of matrix metalloproteinase triple-helical peptidase activity with substrates incorporating fluorogenic L- or D-amino acids. , 2003, Analytical biochemistry.

[25]  I. Nishimoto,et al.  Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations , 1998, Clinical & Experimental Metastasis.

[26]  D. Ruiter,et al.  Matrix metalloproteinases in human melanoma. , 2000, The Journal of investigative dermatology.

[27]  P. Wielopolski,et al.  Multimodality Imaging Reveals a Gradual Increase in Matrix Metalloproteinase Activity at Aneurysmal Lesions in Live Fibulin-4 Mice , 2010, Circulation. Cardiovascular imaging.

[28]  M. Stack,et al.  Selective Hydrolysis of Triple-helical Substrates by Matrix Metalloproteinase-2 and -9* , 2003, The Journal of Biological Chemistry.

[29]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[30]  H. Verspaget,et al.  Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. , 1996, British Journal of Cancer.

[31]  K. Nicolay,et al.  Tumor Targeting of MMP-2/9 Activatable Cell-Penetrating Imaging Probes Is Caused by Tumor-Independent Activation , 2011, The Journal of Nuclear Medicine.

[32]  Shiva Gautam,et al.  Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. , 2004, The Biochemical journal.

[33]  Molecular imaging of MMP expression and therapeutic MMP inhibition. , 2002, Academic radiology.

[34]  J. Becker,et al.  Coexpression of Integrin αvβ3 and Matrix Metalloproteinase-2 (MMP-2) Coincides with MMP-2 Activation: Correlation with Melanoma Progression , 2000 .

[35]  Hamid Dehghani,et al.  Endoscopic, rapid near-infrared optical tomography. , 2006, Optics letters.

[36]  Ralph Weissleder,et al.  Developing a peptide-based near-infrared molecular probe for protease sensing. , 2004, Bioconjugate chemistry.

[37]  M. Kaiser-Kupfer,et al.  Retinal visualization in an eye with corneal crystals using indocyanine green videoangiography. , 2002, American journal of ophthalmology.

[38]  Dominique Trudel,et al.  Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. , 2003, Cancer research.

[39]  J. Becker,et al.  Expression and activation of matrix metalloproteinase‐2 (MMP‐2) and its co‐localization with membrane‐type 1 matrix metalloproteinase (MT1‐MMP) correlate with melanoma progression , 2000 .

[40]  Samuel Achilefu,et al.  Monitoring the biodegradation of dendritic near-infrared nanoprobes by in vivo fluorescence imaging. , 2008, Molecular pharmaceutics.

[41]  T. Turpeenniemi‐Hujanen,et al.  Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma , 2003, British Journal of Cancer.

[42]  E. Kubista,et al.  MMP-2 and MMP-9 Expression in Breast Cancer-Derived Human Fibroblasts is Differentially Regulated by Stromal-Epithelial Interactions , 2002, Breast Cancer Research and Treatment.

[43]  Roger Y Tsien,et al.  Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. , 2009, Integrative biology : quantitative biosciences from nano to macro.

[44]  M. Schaefer,et al.  Low Molecular Weight Inhibitors in Corneal Ulceration a , 1994, Annals of the New York Academy of Sciences.

[45]  J. Seltzer,et al.  Cleavage specificity of human skin type IV collagenase (gelatinase). Identification of cleavage sites in type I gelatin, with confirmation using synthetic peptides. , 1990, The Journal of biological chemistry.

[46]  A Yasui,et al.  Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. , 1990, European journal of biochemistry.

[47]  Xiaojuan Li,et al.  Characterization of Human Osteoarthritic Cartilage Using Optical and Magnetic Resonance Imaging , 2011, Molecular Imaging and Biology.

[48]  S. Mobashery,et al.  Sulfonate-containing thiiranes as selective gelatinase inhibitors. , 2011, ACS medicinal chemistry letters.

[49]  L. Matrisian,et al.  Imaging matrix metalloproteinases in cancer , 2008, Cancer and Metastasis Reviews.

[50]  A. Popel,et al.  A Biochemical Model of Matrix Metalloproteinase 9 Activation and Inhibition* , 2007, Journal of Biological Chemistry.

[51]  P. Glynn,et al.  Expression of MMP‐2 and MMP‐9, their inhibitors, and the activator MT1‐MMP in primary breast carcinomas , 1999, The Journal of pathology.

[52]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.